Compare ASTRAZENECA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs LUPIN - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA LUPIN ASTRAZENECA PHARMA/
LUPIN
 
P/E (TTM) x 114.6 -128.8 - View Chart
P/BV x 33.5 2.9 1,165.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   LUPIN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
LUPIN
Mar-19
ASTRAZENECA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,278986 129.6%   
Low Rs883720 122.5%   
Sales per share (Unadj.) Rs228.4369.5 61.8%  
Earnings per share (Unadj.) Rs10.413.4 77.3%  
Cash flow per share (Unadj.) Rs16.337.4 43.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8303.7 32.5%  
Shares outstanding (eoy) m25.00452.49 5.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.3 204.8%   
Avg P/E ratio x104.263.6 163.8%  
P/CF ratio (eoy) x66.422.8 291.1%  
Price / Book Value ratio x10.92.8 389.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,008386,064 7.0%   
No. of employees `0001.417.7 7.7%   
Total wages/salary Rs m1,53531,513 4.9%   
Avg. sales/employee Rs Th4,210.99,453.8 44.5%   
Avg. wages/employee Rs Th1,132.21,782.0 63.5%   
Avg. net profit/employee Rs Th191.1343.0 55.7%   
INCOME DATA
Net Sales Rs m5,710167,182 3.4%  
Other income Rs m1233,640 3.4%   
Total revenues Rs m5,833170,822 3.4%   
Gross profit Rs m46328,822 1.6%  
Depreciation Rs m14710,850 1.4%   
Interest Rs m03,078 0.0%   
Profit before tax Rs m43818,534 2.4%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1799,017 2.0%   
Profit after tax Rs m2596,066 4.3%  
Gross profit margin %8.117.2 47.0%  
Effective tax rate %40.848.7 84.0%   
Net profit margin %4.53.6 125.1%  
BALANCE SHEET DATA
Current assets Rs m3,209138,536 2.3%   
Current liabilities Rs m2,07061,299 3.4%   
Net working cap to sales %20.046.2 43.2%  
Current ratio x1.62.3 68.6%  
Inventory Days Days7284 86.3%  
Debtors Days Days35112 31.1%  
Net fixed assets Rs m790127,516 0.6%   
Share capital Rs m50905 5.5%   
"Free" reserves Rs m2,419136,517 1.8%   
Net worth Rs m2,469137,422 1.8%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m4,605279,494 1.6%  
Interest coverage xNM7.0-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.20.6 207.3%   
Return on assets %5.63.3 172.0%  
Return on equity %10.54.4 237.7%  
Return on capital %17.78.9 199.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30059,414 0.5%   
Fx outflow Rs m2,01522,282 9.0%   
Net fx Rs m-1,71537,132 -4.6%   
CASH FLOW
From Operations Rs m8816,660 0.5%  
From Investments Rs m-94-32,825 0.3%  
From Financial Activity Rs mNA7,441 0.0%  
Net Cashflow Rs m-6-8,724 0.1%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 31.9 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   12,856 98,259 13.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

June WPI Inflation Data, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets fell sharply, led by weak Asian equities as worries of new lockdowns to stem surging coronavirus cases kept investors cautious worldwide.

Related Views on News

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 14, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS